Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study.

导出 LinkOut

翻译打印收藏纠错

作者： Jiayu,Wang ^[1] ; Yunjiang,Liu ^[2] ; Qingyuan,Zhang ^[3] ; Wei,Li ^[4] ; Jifeng,Feng ^[5] ; Xiaojia,Wang ^[6] ; Jianmin,Fang ^[7] ; Yiqun,Han ^[1] ; Binghe,Xu ^[1]

作者单位： Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China. ^[1] Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China. ^[2] Department of Breast Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China. ^[3] Department of Medical Oncology, The First Hospital of Jilin University, Changchun, Jilin, P. R. China. ^[4] Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, P. R. China. ^[5] Department of Breast Medicine, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China. ^[6] School of Life Science and Technology, Tongji University, Shanghai, P. R. China. ^[7]

关键词 HER2‐low HER2‐overexpression antibody‐drug conjugate breast cancer clinical trials disitamab vedotin

主题词人类(Humans);女(雌)性(Female);中年人(Middle Aged);乳腺肿瘤(Breast Neoplasms);免疫轭合物(Immunoconjugates);老年人(Aged);成年人(Adult);老年人, 80以上(Aged, 80 and over)

DOI 10.1002/cac2.12577

PMID 38940019

发布时间 2024-07-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer communications (London, England)

2024年44卷7期

833-851页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study.

Cancer communications (London, England)

相似文献

Cancer communications (London, England)

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study.

Cancer communications (London, England)

相似文献

Cancer communications (London, England)

相关期刊

检索历史清除